HH
Therapeutic Areas
Corcept Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Relacorilant (Lifyorli®) | Hypercortisolism (Cushing syndrome) - GRACE | Phase 3 |
| Relacorilant | Hypercortisolism from adrenal adenoma/hyperplasia - GRADIENT | Phase 3 |
| Korlym® | Prevalence/Treatment in difficult-to-control type 2 diabetes (CATALYST) | Phase 4 |
| N/A (Screening) | Prevalence of hypercortisolism in resistant hypertension (MOMENTUM) | Phase 4 |
| Relacorilant + Nab-paclitaxel | Platinum-resistant ovarian cancer (ROSELLA) | Phase 3 |
| Relacorilant + Nab-paclitaxel + Bevacizumab | Platinum-resistant ovarian cancer (BELLA Arm A) | Phase 2 |
| Relacorilant + Gemcitabine/Nab-paclitaxel | Pancreatic cancer (TRIDENT) | Phase 2 |
| Nenocorilant + Nivolumab | Solid Tumors (SYNERGY) | Phase 2 |
Leadership Team at Corcept Therapeutics
JK
Joseph K. Belanoff, M.D.
Chief Executive Officer, President and Director
AF
Amy Flood
Chief Human Resources and Communications Officer
WG
William Guyer, PharmD
Chief Development Officer
JL
J.D. Lyon
Chief Accounting and Technology Officer
SM
Sean Maduck
President, Endocrinology
AM
Atabak Mokari
Chief Financial Officer
CR
Charles Robb
Chief Business Officer
MT
Monica Tellado
President, Emerging Markets
RV
Roberto Vieira
President, Oncology
JN
James N. Wilson
Chairman of the Board